Reflection Asset Management Takes $516,000 Position in Henry Schein, Inc. $HSIC

Reflection Asset Management purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,833 shares of the company’s stock, valued at approximately $516,000.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after buying an additional 9,756 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after buying an additional 229 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Henry Schein in the 1st quarter worth $676,000. Cetera Investment Advisers increased its stake in shares of Henry Schein by 12.9% in the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock worth $406,000 after acquiring an additional 637 shares during the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Henry Schein by 0.8% during the 2nd quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock worth $16,154,000 after acquiring an additional 1,669 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $79.92 on Friday. The business has a 50-day moving average price of $75.96 and a 200 day moving average price of $76.40. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $9.10 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 1.54 and a beta of 0.82. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same period in the previous year, the firm earned $1.15 EPS. Henry Schein’s revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts expect that Henry Schein, Inc. will post 5.32 EPS for the current year.

Insider Activity

In related news, Director William K. Daniel acquired 10,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the acquisition, the director owned 20,000 shares in the company, valued at $1,383,800. The trade was a 100.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.89% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on HSIC. Morgan Stanley reissued an “underweight” rating and set a $64.00 price target (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Wells Fargo & Company lifted their target price on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. Leerink Partners reiterated a “market perform” rating on shares of Henry Schein in a report on Monday, March 9th. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, Citigroup began coverage on shares of Henry Schein in a research note on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price target for the company. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $87.85.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.